1. Regeneron Pharmaceuticals. FDA approves first-in-class EVKEEZATM (evinacumab-dgnb) for patients with ultra-rare inherited form of high cholesterol [media release]. 11 Feb 2021. https://investor.regeneron.com.
2. Regeneron Pharmaceuticals. Regeneron pipeline. 2021. https://www.regeneron.com/pipeline. Accessed 30 Mar 2021.
3. Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017;377(3):296–7.
4. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–20.
5. Regeneron Pharmaceuticals. EVKEEZA™ (evinacumab-dgnb) injection: US prescribing information. 2021. https://www.regeneron.com/sites/default/files/Evkeeza_PI.pdf. Accessed 15 Feb 2021.